NCT03418038 2026-04-16
Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia
Mayo Clinic
Phase 2 Recruiting
Clinical Trials
20 trialsNCT03132454 2026-04-15
Palbociclib and Sorafenib, Decitabine, or Dexamethasone in Treating Patients With Recurrent or Refractory Leukemia
M.D. Anderson Cancer Center
Phase 1 Active not recruiting
NCT05038592 2026-04-14
Phase I/II Study of Tagraxofusp in Combination With Decitabine for Patients With Myelomonocytic/Myeloproliferative Neoplasm and High Risk Myelodysplastic Syndromes
M.D. Anderson Cancer Center
Phase 1/2 Active not recruiting
NCT01627041 2026-04-13
Decitabine, Cytarabine, and Daunorubicin Hydrochloride in Treating Patients With Acute Myeloid Leukemia
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT01861314 2026-04-13
Bortezomib, Sorafenib Tosylate, and Decitabine in Treating Patients With Acute Myeloid Leukemia
National Cancer Institute (NCI)
Phase 1 Active not recruiting
NCT03041688 2026-04-13
Testing a New Chemotherapy Drug, KRT-232 (AMG-232) in Combination With Decitabine and Venetoclax in Patients With Acute Myeloid Leukemia
National Cancer Institute (NCI)
Phase 1 Active not recruiting
NCT07012044 2026-04-13
A Study to Find the Highest Dose of Cedazuridine and Decitabine Combination With Filgrastim as a Treatment Option After Hematopoietic Stem Cell Transplant in Children With High-Risk Acute Myeloid Leukemia
National Cancer Institute (NCI)
Phase 1 Not yet recruiting
NCT07177079 2026-04-09
High-dose Ascorbate (HDA) in Combination With Standard of Care Azacitidine and Venetoclax in Acute Myeloid Leukemia (AML)
University of Iowa
Phase 1 Recruiting
NCT03240211 2026-04-07
Study of Pembrolizumab Combined With Decitabine and Pralatrexate in PTCL and CTCL
University of Virginia
Phase 1 Active not recruiting
NCT03017131 2026-04-06
Genetically Modified T Cells and Decitabine in Treating Patients With Recurrent or Refractory Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Roswell Park Cancer Institute
Phase 1 Active not recruiting
NCT07511062 2026-04-06
Axatilimab Combined With Decitabine/Venetoclax for the Treatment of TP53-mutated AML
Northside Hospital, Inc.
Phase 1 Not yet recruiting
NCT02204085 2026-04-03
A Phase I/II Trial of the MUC1 Inhibitor, GO-203-2C in Patients With Relapsed or Refractory Acute Myeloid Leukemia
Beth Israel Deaconess Medical Center
Phase 1/2 Completed
NCT07374029 2026-04-03
Adoptive T Cell Therapy With DC/AML Fusion Vaccine Plus Decitabine and Venetoclax in AML
Beth Israel Deaconess Medical Center
Phase 1 Not yet recruiting
NCT06327685 2026-04-01
Avapritinib With Decitabine in Patients With SM-AHN
H. Lee Moffitt Cancer Center and Research Institute
Phase 1 Recruiting
NCT07505160 2026-04-01
Efficacy and Safety of Lisafotoclax Plus Decitabine and Homoharringtonine in Venetoclax/Azacitidine Pretreated AML Patients
Second Affiliated Hospital, School of Medicine, Zhejiang University
Phase 2 Not yet recruiting
NCT00801489 2026-03-30
Fludarabine Phosphate, Cytarabine, Filgrastim-sndz, Gemtuzumab Ozogamicin, and Idarubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
M.D. Anderson Cancer Center
Phase 2 Recruiting
NCT04980404 2026-03-30
Inqovi Maintenance Therapy in Myeloid Neoplasms
Massachusetts General Hospital
Phase 1 Active not recruiting
NCT05796570 2026-03-19
MORE
Dana-Farber Cancer Institute
Phase 2 Recruiting
NCT06379360 2026-03-19
Maintenance Therapy of Hypomethylating Agent (HMA) in Favorable Risk Acute Myeloid Leukemia (AML) Patients
The First Affiliated Hospital of Soochow University
Phase 2 Recruiting
NCT05636514 2026-03-18
CELESTIAL-MDS
Clinical Hub for Interventional Research (CHOIR)
Phase 1 Recruiting